Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) - Apr 20, 2023 - "During 2023, the Company expects to accomplish the following key business objectives: (i) Complete key enrollment and site expansion activities in the ReSPECT-GBM Phase 2b trial for full trial enrollment by year-end 2024; (ii) Initiate the Phase 1 ReSPECT-PBC trial for pediatric patients with ependymoma and high-grade glioma; (iii) Complete key preclinical synergistic drug combination studies of rhenium (186Re) obisbemeda and systemic therapies for GBM and LM."
Enrollment status • New P1 trial • Preclinical • Brain Cancer • CNS Tumor • Ependymoma • Glioblastoma • Glioma • Oncology • Solid Tumor
|